MAFIP is a tumor suppressor in cervical cancer that inhibits activation of the nuclear factor-kappa B pathway
Authors:
Open Access
- 11 August 2011
- journal article
- Published by Wiley in Cancer Science
- Vol. 102 (11) , 2043-2050
Abstract
Cervical cancer is the second most common cancer in women. Inactivation of tumor suppressor genes underlies the transformation and progression of cervical cancer. Previously, we reported MAFIP can inhibit the growth of human cervical cancer HeLa cells. In this study, MAFIP was found to be downregulated in cervical intraepithelial neoplasia tissues. Induced expression of MAFIP in HeLa cells strongly inhibited tumor formation in nude mice, confirming its tumor suppressor activity in vivo. Overexpression of MAFIP inhibited activation of the NF-κB pathway, a commonly active pathway in cancer cells, by preventing the phosphorylation of IKK and IκBα, degradation of IκBα and the nuclear localization of p65. Induction of c-myc, an oncogene controlled by NF-κB, was severely impaired in the cells overexpressing MAFIP. In contrast, knockdown of MAFIP by siRNA activated the NF-κB pathway and promoted cell proliferation. These data suggest MAFIP functions as a tumor suppressor in cervical cancer in part by inhibiting activation of the NF-κB pathway. (Cancer Sci 2011; 102: 2043–2050)Keywords
This publication has 56 references indexed in Scilit:
- The Fission Yeast Inhibitor of Growth (ING) Protein Png1p Functions in Response to DNA DamageJournal of Biological Chemistry, 2010
- ZBRK1 Acts as a Metastatic Suppressor by Directly Regulating MMP9 in Cervical CancerCancer Research, 2010
- NF-κB and cancer: how intimate is this relationshipMolecular and Cellular Biochemistry, 2009
- Retracted: A cell cycle regulatory network controlling NF‐κB subunit activity and functionThe EMBO Journal, 2007
- A novel cervical cancer suppressor 3 (CCS‐3) interacts with the BTB domain of PLZF and inhibits the cell growth by inducing apoptosisFEBS Letters, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Constitutive activation of nuclear factor-kB: preferntial homodimerization of p50 subunits in cervical carcinomaFrontiers in Bioscience-Landmark, 2005
- Inhibition of NF-κB activation by merlinBiochemical and Biophysical Research Communications, 2002
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999